Medicus Pharma Ltd (NASDAQ:MDCX) Given Consensus Rating of “Moderate Buy” by Brokerages

Medicus Pharma Ltd (NASDAQ:MDCX) has earned a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $23.50.

MDCX has been the subject of several research analyst reports. Zacks Research raised shares of Medicus Pharma to a “hold” rating in a research note on Monday, September 15th. D. Boral Capital restated a “buy” rating and issued a $27.00 price objective on shares of Medicus Pharma in a report on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Medicus Pharma in a research report on Monday.

Medicus Pharma Stock Up 3.4%

MDCX stock opened at $1.51 on Friday. Medicus Pharma has a 52-week low of $1.45 and a 52-week high of $8.94. The stock has a market cap of $33.26 million and a price-to-earnings ratio of -0.70. The business has a fifty day moving average of $2.06 and a two-hundred day moving average of $2.35.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.27). As a group, sell-side analysts anticipate that Medicus Pharma will post -1.14 EPS for the current year.

Institutional Investors Weigh In On Medicus Pharma

Institutional investors have recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new stake in shares of Medicus Pharma in the 3rd quarter valued at $59,000. Yorkville Advisors Global LP acquired a new position in Medicus Pharma in the 3rd quarter valued at about $532,000. Private Advisor Group LLC increased its stake in Medicus Pharma by 3.8% during the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock worth $351,000 after purchasing an additional 5,500 shares during the period. Brave Asset Management Inc. acquired a new stake in shares of Medicus Pharma during the third quarter worth about $46,000. Finally, Osaic Holdings Inc. lifted its position in shares of Medicus Pharma by 180.0% during the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock worth $42,000 after purchasing an additional 9,000 shares in the last quarter.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.